Literature DB >> 15183815

Intravitreal triamcinolone acetonide for the management of diabetic papillopathy.

Christiane E Al-Haddad1, Fadi A Jurdi, Ziad F Bashshur.   

Abstract

PURPOSE: To present a case of severe drop in vision in both eyes caused by diabetic papillopathy that was treated with an intravitreal injection of triamcinolone acetonide.
DESIGN: Interventional case report.
METHODS: A diabetic patient with bilateral diabetic papillopathy and drop in vision received sequential intravitreal triamcinolone acetonide injections to both eyes.
RESULTS: Within 2 weeks of intravitreal injection, vision improved from counting fingers at 1 m to 20/50 OS, and from counting fingers at 4 m to 20/40 OD. This improvement was accompanied by resolution of disk swelling and macular edema. Vision remained stable in both eyes at 20/40 for 8 months of follow-up. No elevation of intraocular pressure beyond 21 mm Hg was noted at any time.
CONCLUSION: Diabetic papillopathy with severe drop in vision can be treated with intravitreal triamcinolone acetonide injection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183815     DOI: 10.1016/j.ajo.2004.01.032

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  9 in total

1.  Resolution of diabetic papillopathy with a single intravitreal injection of bevacizumab combined with triamcinolone acetonide.

Authors:  Jing Feng; Jin-Feng Qu; Yan-Rong Jiang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-06-26       Impact factor: 3.117

2.  Intravitreal triamcinolone acetonide for treatment of acute nonarteritic anterior ischemic optic neuropathy.

Authors:  Jost B Jonas; Ulrich H Spandau; Bjoern Harder; Gangolf Sauder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-05-04       Impact factor: 3.117

3.  Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema.

Authors:  U H M Spandau; M Derse; P Schmitz-Valckenberg; C Papoulis; J B Jonas
Journal:  Br J Ophthalmol       Date:  2005-08       Impact factor: 4.638

4.  Diabetic papillopathy with macular edema treated with intravitreal bevacizumab.

Authors:  Ahmed S Al-Hinai; Mohammed S Al-Abri; Rayah H Al-Hajri
Journal:  Oman J Ophthalmol       Date:  2011-09

5.  Dose dependent effects of intravitreal triamcinolone acetonide on diffuse diabetic macular edema.

Authors:  Joon Sung Bae; Sung Joon Park; I Rum Ham; Tae Gon Lee
Journal:  Korean J Ophthalmol       Date:  2009-06-09

Review 6.  Ocular associations of diabetes other than diabetic retinopathy.

Authors:  V Swetha E Jeganathan; Jie Jin Wang; Tien Yin Wong
Journal:  Diabetes Care       Date:  2008-09       Impact factor: 19.112

7.  Diabetic papillopathy treated with intravitreal ranibizumab.

Authors:  Mine Yildirim; Deniz Kilic; Mehmet Emin Dursun; Birgul Dursun
Journal:  Int Med Case Rep J       Date:  2017-03-22

8.  The evaluation of patients with optic disc edema: A retrospective study.

Authors:  Selma Urfalioglu; Gokhan Ozdemir; Mete Guler; Gamze Gizem Duman
Journal:  North Clin Istanb       Date:  2021-04-14

9.  Diabetic papillopathy with macular edema treated with intravitreal ranibizumab.

Authors:  Moosang Kim; Jang-Hun Lee; Seung-Jun Lee
Journal:  Clin Ophthalmol       Date:  2013-11-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.